The androgen receptor (AR) is a member of the nuclear hormone receptor family and plays a central role in the development of the normal prostate and in prostate cancer. The observations from androgen ablation treatment of prostate cancer have indicated that signals mediated through the AR are critical for prostate cancer growth and that alterations both in the AR and its associated proteins may contribute to primary and androgen independent prostate cancer. Understanding the mechanisms through which the AR regulates gene expression should, therefore, provide insight into abnormalities which may contribute to the development of prostate cancer and provide possible targets for future treatment. Recent reports have shown that nuclear hormone receptors must function by directly or indirectly making contacts with other transcriptional factors which include activators, repressors and modulators to mediate the effects on transcription. The major goal of this work is to identify and characterize the proteins which associate with the AR to mediate and/or modulate the effects of the AR on cell growth. The preliminary studies have provided evidence to demonstrate that an AR associated DNA binding protein complex plays a role in the process of AR regulated transcription. This proposal is to biochemically and functionally characterize this AR associated protein complex in detail to determine how it regulates the expressions of two human AR target genes, prostate specific antigen (PSA) and kallikrein 2 (KLK2). The long term goal is to define interactions between the AR and associated proteins in prostate cancer and determine whether these associated proteins can be targeted for the development useful drugs in the treatment of prostate cancer.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
First Independent Research Support & Transition (FIRST) Awards (R29)
Project #
1R29CA070297-01A2
Application #
2395806
Study Section
Pathology B Study Section (PTHB)
Project Start
1997-07-23
Project End
1998-06-30
Budget Start
1997-07-23
Budget End
1998-06-30
Support Year
1
Fiscal Year
1997
Total Cost
Indirect Cost
Name
Beth Israel Deaconess Medical Center
Department
Type
DUNS #
076593722
City
Boston
State
MA
Country
United States
Zip Code
02215
Johnson, Daniel T; Luong, Richard; Lee, Suk Hyung et al. (2013) Deletion of leucine zipper tumor suppressor 2 (Lzts2) increases susceptibility to tumor development. J Biol Chem 288:3727-38
Kwak, Mi Kyung; Johnson, Daniel T; Zhu, Chunfang et al. (2013) Conditional deletion of the Pten gene in the mouse prostate induces prostatic intraepithelial neoplasms at early ages but a slow progression to prostate tumors. PLoS One 8:e53476
Li, Xiaomeng; Zhu, Chunfang; Tu, William H et al. (2011) ZMIZ1 preferably enhances the transcriptional activity of androgen receptor with short polyglutamine tract. PLoS One 6:e25040
Zhu, Chunfang; Luong, Richard; Zhuo, Ming et al. (2011) Conditional expression of the androgen receptor induces oncogenic transformation of the mouse prostate. J Biol Chem 286:33478-88
Zhuo, Ming; Zhu, Chunfang; Sun, JingLucy et al. (2011) The beta-catenin binding protein ICAT modulates androgen receptor activity. Mol Endocrinol 25:1677-88
Tu, William H; Zhu, Chunfang; Clark, Curtis et al. (2010) Efficacy of c-Met inhibitor for advanced prostate cancer. BMC Cancer 10:556
Peng, Yue; Lee, Jane; Zhu, Chunfang et al. (2010) A novel role for protein inhibitor of activated STAT (PIAS) proteins in modulating the activity of Zimp7, a novel PIAS-like protein, in androgen receptor-mediated transcription. J Biol Chem 285:11465-75